Ivy Alwell, APRN
Psychiatric/Mental Health, Adult · Hillsboro, MONPI 1477684009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 327 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,864 and has fallen 88.5% since, to $214 in 2025.
Across 327 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$756
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$529
- Vanda Pharmaceuticals Inc.$423
- Otsuka America Pharmaceutical, Inc.$313
- Johnson & Johnson$302
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,83098%
- Education$982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 102 | $1,406 |
| Supernus Pharmaceuticals, Inc. | 25 | $756 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $529 |
| Vanda Pharmaceuticals Inc. | 26 | $423 |
| Otsuka America Pharmaceutical, Inc. | 15 | $313 |
| Johnson & Johnson | 19 | $302 |
| Lundbeck LLC | 15 | $290 |
| Axsome Therapeutics, Inc. | 10 | $274 |
| Sunovion Pharmaceuticals Inc. | 12 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $179 |
| Corium, LLC | 10 | $155 |
| E.r. Squibb & Sons, L.L.C. | 2 | $142 |
| Eisai Inc. | 6 | $136 |
| Alkermes, Inc. | 6 | $121 |
| Teva Pharmaceuticals USA, Inc. | 7 | $117 |
| Ironshore Pharmaceuticals Inc. | 7 | $111 |
| Almatica Pharma LLC | 4 | $96 |
| Neurocrine Biosciences, Inc. | 5 | $83 |
| Bausch Health US, LLC | 4 | $64 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| Tris Pharma Inc | 3 | $45 |
| Neos Therapeutics, LP | 3 | $45 |
| Noven Therapeutics, LLC | 2 | $28 |
| Indivior Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few psychiatric/mental health, adult providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 18 | $45,544 |
| RexultiBrexpiprazole | 12 | $20,549 |
| Vilazodone Hcl | 11 | $787 |
| Mirtazapine | 31 | $759 |
| Fluoxetine Hcl | 88 | $744 |
| Bupropion XlBupropion Hcl | 26 | $622 |
| Quetiapine Fumarate | 46 | $613 |
| Lamotrigine | 59 | $561 |
| Olanzapine | 31 | $511 |
| Aripiprazole | 29 | $482 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $482 |
| Bupropion Hcl SrBupropion Hcl | 26 | $474 |
| Duloxetine Hcl | 31 | $448 |
| Clonazepam | 41 | $385 |
| Trazodone Hcl | 71 | $362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $423 | $45,54418 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $313 | $20,54912 claims |
| Almatica Pharma LLCSertraline Hcl | $96 | $35827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Missourion file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Hillsboro
- Jeffrey BoatmanSaint Louis$7K
- Veneta RaboinMexico$3K
- Theresa KormosSaint Louis$2K
- Laura RomerSaint Louis$572
- Carolyn GreeningHannibal$475
- Sherry DoneySaint Louis$293
- Janet MurdickFestus$268
- Jeana WilcoxKansas City$194
- Shari HelbigSaint Louis$86
- Donna GrahamSaint Louis$70
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.